Nickhill Bhakta Discusses Unanswered Questions About Survivors of Childhood Cancer
Nickhill Bhakta, MD, fellow at St. Jude Children’s Research Hospital, discusses some unanswered questions about late effects of adult survivors of childhood cancer.
Nickhill Bhakta, MD, fellow at St. Jude Children’s Research Hospital, discusses some unanswered questions about late effects of adult survivors of childhood cancer.
While mortality rates have been going down for this group, Bhakta hopes that more studies will examine if late effects are being reduced as well, giving these survivors a better quality of life. Eventually, a balance between cure and the price down the road will become a major player in designing future trials.
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
March 6th 2024The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
